Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03362060
Recruitment Status : Active, not recruiting
First Posted : December 5, 2017
Last Update Posted : May 10, 2021
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Steven J Isakoff, MD, PhD, Massachusetts General Hospital

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : December 31, 2022
Estimated Study Completion Date : December 31, 2024